<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00546052</url>
  </required_header>
  <id_info>
    <org_study_id>0954A-331</org_study_id>
    <secondary_id>MK0954A-331</secondary_id>
    <secondary_id>2007_030</secondary_id>
    <nct_id>NCT00546052</nct_id>
  </id_info>
  <brief_title>A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)</brief_title>
  <official_title>52 Week Study to Evaluate the Effects of LOSARTAN 50 mg, 100 mg, 100/12.5 mg HCTZ, 100/25 mg HCTZ on Metabolic Parameters, Blood Pressure and Safety in Hypertensive Patients With Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      To determine if a one year treatment Losartan with or without HCTZ at different dosages have
      an effect on metabolic parameters in patients with hypertension and the metabolic syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2005</start_date>
  <completion_date type="Actual">January 1, 2008</completion_date>
  <primary_completion_date type="Actual">January 1, 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hemoglobin A1c Between 52 Weeks and Baseline</measure>
    <time_frame>52 Weeks - Baseline</time_frame>
    <description>Absolute Change in Hemoglobin A1c between 52 week measurement and baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Fasting Blood Glucose Between Baseline and 52 Weeks Assessments</measure>
    <time_frame>52 Weeks - Baseline</time_frame>
    <description>Absolute Change in Fasting Blood Glucose Measurements between Baseline and 52 week assessments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Blood Pressure</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Target Blood Pressure defined as Systolic Blood Pressure/Diastolic Blood Pressure ≤ 140/90 mm Hg at 52 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure Between Baseline and 52 Week Assessments</measure>
    <time_frame>52 Weeks - Baseline</time_frame>
    <description>Absolute change in Systolic Blood Pressure between baseline and 52 week assessments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Blood Pressure Between Baseline and 52 Week Assessments</measure>
    <time_frame>52 Weeks - Baseline</time_frame>
    <description>Absolute change in Diastolic Blood Pressure between baseline and 52 week assessments.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Waist Circumference Between Baseline and 52 Week Assessments</measure>
    <time_frame>52 Weeks - Baseline</time_frame>
    <description>Absolute change in Waist Circumference between baseline and 52 week assessments</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Body Mass Index Between Baseline and 52 Week Assessments</measure>
    <time_frame>52 Weeks - Baseline</time_frame>
    <description>Absolute change in Body Mass Index Baseline and 52 week assessments</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change in Low Density Lipoprotein-C Between Baseline and 52 Week Assessments</measure>
    <time_frame>52 Weeks - Baseline</time_frame>
    <description>Percent Change in LDL-C Between Baseline and 52 week assessments: 100% x [(LDL-C 52 Weeks - LDL-C Baseline) / (LDL-C Baseline)].</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change in High Density Lipoprotein-C Between Baseline and 52 Week Assessments</measure>
    <time_frame>52 Weeks - Baseline</time_frame>
    <description>Percent Change in HDL-C Between Baseline and 52 week assessments: 100% x [(HDL-C 52 Weeks - HDL-C 52 Baseline) / (HDL-C Baseline)].</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change in Triglycerides Between Baseline and 52 Week Assessments</measure>
    <time_frame>52 Weeks - Baseline</time_frame>
    <description>Percent Change in Triglycerides Between Baseline and 52 week assessments: 100% x [(Triglycerides 52 Weeks - Triglycerides Baseline) / (Triglycerides Baseline)].</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change in Total Cholesterol Between Baseline and 52 Week Assessments</measure>
    <time_frame>52 Weeks - Baseline</time_frame>
    <description>Percent Change in Total Cholesterol Between Baseline and 52 week assessments: 100% x [(Total Cholesterol 52 weeks - Total Cholesterol Baseline) / (Total Cholesterol Baseline)].</description>
  </other_outcome>
  <other_outcome>
    <measure>Absolute Change in Uric Acid Between Baseline and 52 Week Assessments</measure>
    <time_frame>52 Weeks - Baseline</time_frame>
    <description>Absolute Change in Uric Acid Between Baseline and 52 week assessments: Uric Acid 52 weeks - Uric Acid Baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Absolute Change in C Reactive Protein Between Baseline and 52 Week Assessments</measure>
    <time_frame>52 Weeks - Baseline</time_frame>
    <description>Absolute Change in C Reactive Protein Between Baseline and 52 week assessments: C Reactive Protein 52 weeks - C Reactive Protein Baseline.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1738</enrollment>
  <condition>Hypertension</condition>
  <condition>Metabolic Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan (MK0954) / Losartan + HCTZ (MK0954A)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>losartan potassium (+) hydrochlorothiazide</intervention_name>
    <description>All patients received Losartan 50mg at Visit 2 titrated to Losartan 100mg (if target BP not achieved) titrated to Losartan 100mg + HCTZ 12.5mg (if necessary) up to Losartan 100mg + HCTZ 25mg. Duration of treatment was one year.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Cozaar/Hyzaar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  An Adult Patient (At Least 18 Years Of Age) With A Clinical Identification Of The
             Metabolic Syndrome Using The IDF Definition:

               -  abdominal (central) obesity as defined by the waist circumference in men of &gt; 102
                  cm and women of &gt; 88 cm or a BMI equal or greater than 30 kg/m2

        and untreated hypertension with bp equal or greater than 140/90 mm Hg but bp &lt; 180/110 mm
        Hg

        or a patient receiving one or two antihypertensive agent(s) (diuretics, ace inhibitors,
        angiotensin ii receptor blockers, calcium channel blockers and beta-blockers will need to
        be discontinued) and whose blood pressure is not controlled:

          -  bp equal or greater than 140/90 mm Hg but equal or less than 160/100 mm Hg

        or a patient whose hypertension is controlled (&lt; 140/90 mm hg) with a single
        anti-hypertensive agent (diuretics, ace inhibitors, and angiotensin II receptor blockers,
        calcium channel blockers and beta-blockers will need to be discontinued) but who is
        unsatisfied or experiencing side effects warranting a discontinuation of the previous
        treatment and at one of the following:

          -  Fasting plasma glucose equal or greater than 5.6 mmol/L and &lt; 7.0 mmol/L

          -  Triglycerides &gt; 1.7 mmol/L or specific treatment for this lipid abnormality

          -  HDL-c in men &lt; 0.9 mmol/L and in women &lt; 1.1 mmol/L or specific treatment for this
             lipid abnormality

        Exclusion Criteria:

          -  A Patient With A Diagnosis Of Type II Diabetes Defined As Fasting Blood Glucose Level
             Equal Or Greater Than 7.0 Mmol/L Or A 2hpg In A 75-G OGTT Equal Or Greater Than 11.1
             Mol/L Or Using Any Anti-Hyperglycemic Agents

          -  Known Secondary Hypertension Of Any Aetiology (E.G., Uncorrected Renal Artery
             Stenosis, Malignant Hypertension, Or Hypertensive Encephalopathy)

          -  Patient Intolerant To Any Component Of Losartan 50 Mg / Losartan 100 Mg / Losartan 100
             Mg + Hctz 12.5 Mg / Losartan 100 Mg + Hctz 25 Mg Or With A Documented History Of
             Angioedema

          -  Patient With Confirmed Clinically Significant Renal Or Hepatic Dysfunction And/Or
             Electrolyte Imbalance On The Basis Of The Case History Or A Recent Laboratory Test
             (Serum Creatinine &gt; 130 Mmol/L Or Creatinine Clearance &lt; 45 Ml/Min, Ast &gt; 2 Times
             Above The Normal Range, Alt &gt; 2 Times Above The Normal Range, Serum Potassium &lt; 3.5 Or
             &gt; 5.5 Meq/L)

          -  Patient With Symptomatic Heart Failure (Classes 3 And 4)

          -  Patient With A Prior Myocardial Infarction Or Stroke Within The Last 6 Months

          -  Patient Who Has Undergone Percutaneous Coronary Angioplasty Or Coronary Artery Bypass
             Within The Last 3 Months

          -  Pregnant Woman Or A Woman Of Childbearing Potential
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <results_reference>
    <citation>Racine N, Hamet P, Sampalis JS, Longo N, Bastien N. A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome. J Hum Hypertens. 2010 Nov;24(11):739-48. doi: 10.1038/jhh.2010.3. Epub 2010 Feb 11.</citation>
    <PMID>20147971</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2007</study_first_submitted>
  <study_first_submitted_qc>October 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2007</study_first_posted>
  <results_first_submitted>January 8, 2009</results_first_submitted>
  <results_first_submitted_qc>May 4, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 23, 2009</results_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First Patient In: 12-Sep-2005 Last Patient In: 29-Dec-2006 Last Patient Last Visit: 31-Jan-08 Total number of Sites (General Practitioners and Family Physicians in Canada): 209</recruitment_details>
      <pre_assignment_details>24 patients not included in the Intention to Treat (ITT) analysis because they did not receive study medication and had no follow up visits. Total ITT population = 1714.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Losartan +/- Hydrochlorothiazide</title>
          <description>Patients could be titrated up from Cozaar 50 mg to Cozaar 100mg to losartan 100 mg + Hydrochlorothiazide 12.5 mg and losartan 100mg/ Hydrochlorothiazide 25 mg, in sequence at any subsequent visits only if needed to obtain Blood Pressure under 140/90 mm Hg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1738"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 4</title>
              <participants_list>
                <participants group_id="P1" count="1714"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 8</title>
              <participants_list>
                <participants group_id="P1" count="1680"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 12</title>
              <participants_list>
                <participants group_id="P1" count="1650"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 32</title>
              <participants_list>
                <participants group_id="P1" count="1583"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 52</title>
              <participants_list>
                <participants group_id="P1" count="1511"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1511"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="227"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non Compliance</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Losartan +/- Hydrochlorothiazide</title>
          <description>Patients could be titrated up from Cozaar 50 mg to Cozaar 100mg to losartan 100 mg + Hydrochlorothiazide 12.5 mg and losartan 100mg/ Hydrochlorothiazide 25 mg, in sequence at any subsequent visits only if needed to obtain Blood Pressure under 140/90 mm Hg.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1714"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.93" spread="11.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=45.00</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45.01 - 52.00</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52.01 - 58.00</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>58.01 - 65.00</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65.00</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="734"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>Kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.23" spread="5.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-Reactive Protein</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.4" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90.54" spread="8.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Blood Glucose</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.7" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart Rate</title>
          <units>Beats per Minute (BPM)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c</title>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.71" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High Density Lipoprotein-C</title>
          <units>mol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.23" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low Density Lipoprotein-C</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.17" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148.22" spread="10.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.36" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.16" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Uric Acid</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="365.8" spread="85.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kilograms (Kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92.5" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Hemoglobin A1c Between 52 Weeks and Baseline</title>
        <description>Absolute Change in Hemoglobin A1c between 52 week measurement and baseline value.</description>
        <time_frame>52 Weeks - Baseline</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan +/- Hydrochlorothiazide</title>
            <description>Patients that completed 52 weeks of treatment and were &gt;= 80% compliant with the study medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin A1c Between 52 Weeks and Baseline</title>
          <description>Absolute Change in Hemoglobin A1c between 52 week measurement and baseline value.</description>
          <population>Per Protocol</population>
          <units>Percent</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1511"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Single Cohort Study. Statistical Analysis is based on change from baseline. Null hypothesis value is + 0.5%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.999</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.02</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.74</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Fasting Blood Glucose Between Baseline and 52 Weeks Assessments</title>
        <description>Absolute Change in Fasting Blood Glucose Measurements between Baseline and 52 week assessments.</description>
        <time_frame>52 Weeks - Baseline</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan +/- Hydrochlorothiazide</title>
            <description>Patients that completed 52 weeks of treatment and were &gt;= 80% compliant with the study medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Blood Glucose Between Baseline and 52 Weeks Assessments</title>
          <description>Absolute Change in Fasting Blood Glucose Measurements between Baseline and 52 week assessments.</description>
          <population>Per Protocol</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1511"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Single Cohort Study. Statistical Analysis is based on change from baseline. Null hypothesis value is + 0.5mmol/L.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.999</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.04</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.62</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Blood Pressure</title>
        <description>Target Blood Pressure defined as Systolic Blood Pressure/Diastolic Blood Pressure ≤ 140/90 mm Hg at 52 weeks</description>
        <time_frame>52 Weeks</time_frame>
        <population>ITT and Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Total</title>
            <description>All patients enrolled (signed the informed consent).</description>
          </group>
          <group group_id="O2">
            <title>Overall Intend to Treat</title>
            <description>All patients enrolled and receiving at least one dose of study drug and having at least one follow up visit.</description>
          </group>
          <group group_id="O3">
            <title>Overall Per Protocol</title>
            <description>All patients completing the 52 week study follow up.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Blood Pressure</title>
          <description>Target Blood Pressure defined as Systolic Blood Pressure/Diastolic Blood Pressure ≤ 140/90 mm Hg at 52 weeks</description>
          <population>ITT and Per Protocol</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1738"/>
                <count group_id="O2" value="1714"/>
                <count group_id="O3" value="1511"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Achieved Target Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1200"/>
                    <measurement group_id="O2" value="1200"/>
                    <measurement group_id="O3" value="1200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did NOT achieve target Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="538"/>
                    <measurement group_id="O2" value="514"/>
                    <measurement group_id="O3" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic Blood Pressure Between Baseline and 52 Week Assessments</title>
        <description>Absolute change in Systolic Blood Pressure between baseline and 52 week assessments.</description>
        <time_frame>52 Weeks - Baseline</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan +/- Hydrochlorothiazide</title>
            <description>Patients that completed 52 weeks of treatment and were &gt;= 80% compliant with the study medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure Between Baseline and 52 Week Assessments</title>
          <description>Absolute change in Systolic Blood Pressure between baseline and 52 week assessments.</description>
          <population>Per Protocol</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1511"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.95" spread="13.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Single Cohort Study. Statistical Analysis is based on change from baseline. Null hypothesis value is 0 mm Hg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-16.95</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>13.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-17.62</ci_lower_limit>
            <ci_upper_limit>-16.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diastolic Blood Pressure Between Baseline and 52 Week Assessments</title>
        <description>Absolute change in Diastolic Blood Pressure between baseline and 52 week assessments.</description>
        <time_frame>52 Weeks - Baseline</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan +/- Hydrochlorothiazide</title>
            <description>Patients that completed 52 weeks of treatment and were &gt;= 80% compliant with the study medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic Blood Pressure Between Baseline and 52 Week Assessments</title>
          <description>Absolute change in Diastolic Blood Pressure between baseline and 52 week assessments.</description>
          <population>Per Protocol</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1511"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.84" spread="8.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Single Cohort Study. Statistical Analysis is based on change from baseline. Null hypothesis value is 0 mm Hg.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.84</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>8.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-10.29</ci_lower_limit>
            <ci_upper_limit>-9.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Waist Circumference Between Baseline and 52 Week Assessments</title>
        <description>Absolute change in Waist Circumference between baseline and 52 week assessments</description>
        <time_frame>52 Weeks - Baseline</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan +/- Hydrochlorothiazide</title>
            <description>Patients that completed 52 weeks of treatment and were &gt;= 80% compliant with the study medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist Circumference Between Baseline and 52 Week Assessments</title>
          <description>Absolute change in Waist Circumference between baseline and 52 week assessments</description>
          <population>Per Protocol</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1511"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" spread="5.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Single Cohort Study. Statistical Analysis is based on change from baseline. Null Hypothesis value is 0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.3</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.4</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Body Mass Index Between Baseline and 52 Week Assessments</title>
        <description>Absolute change in Body Mass Index Baseline and 52 week assessments</description>
        <time_frame>52 Weeks - Baseline</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan +/- Hydrochlorothiazide</title>
            <description>Patients that completed 52 weeks of treatment and were &gt;= 80% compliant with the study medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Mass Index Between Baseline and 52 Week Assessments</title>
          <description>Absolute change in Body Mass Index Baseline and 52 week assessments</description>
          <population>Per Protocol</population>
          <units>Kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1511"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="5.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Single Cohort Study. Statistical Analysis is based on change from baseline. Null Hypothesis value is 0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.3</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.20</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change in Low Density Lipoprotein-C Between Baseline and 52 Week Assessments</title>
        <description>Percent Change in LDL-C Between Baseline and 52 week assessments: 100% x [(LDL-C 52 Weeks – LDL-C Baseline) / (LDL-C Baseline)].</description>
        <time_frame>52 Weeks - Baseline</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan +/- Hydrochlorothiazide</title>
            <description>Patients that completed 52 weeks of treatment and were &gt;= 80% compliant with the study medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Low Density Lipoprotein-C Between Baseline and 52 Week Assessments</title>
          <description>Percent Change in LDL-C Between Baseline and 52 week assessments: 100% x [(LDL-C 52 Weeks – LDL-C Baseline) / (LDL-C Baseline)].</description>
          <population>Per Protocol</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1511"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.49" spread="32.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Single Cohort Study. Statistical Analysis is based on change from baseline. Null Hypothesis value is 0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.084</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.5</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>32.1</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change in High Density Lipoprotein-C Between Baseline and 52 Week Assessments</title>
        <description>Percent Change in HDL-C Between Baseline and 52 week assessments: 100% x [(HDL-C 52 Weeks – HDL-C 52 Baseline) / (HDL-C Baseline)].</description>
        <time_frame>52 Weeks - Baseline</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan +/- Hydrochlorothiazide</title>
            <description>Patients that completed 52 weeks of treatment and were &gt;= 80% compliant with the study medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in High Density Lipoprotein-C Between Baseline and 52 Week Assessments</title>
          <description>Percent Change in HDL-C Between Baseline and 52 week assessments: 100% x [(HDL-C 52 Weeks – HDL-C 52 Baseline) / (HDL-C Baseline)].</description>
          <population>Per Protocol</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1511"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="17.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Single Cohort Study. Statistical Analysis is based on change from baseline. Null Hypothesis value is 0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.654</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>18.0</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change in Triglycerides Between Baseline and 52 Week Assessments</title>
        <description>Percent Change in Triglycerides Between Baseline and 52 week assessments: 100% x [(Triglycerides 52 Weeks – Triglycerides Baseline) / (Triglycerides Baseline)].</description>
        <time_frame>52 Weeks - Baseline</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan +/- Hydrochlorothiazide</title>
            <description>Patients that completed 52 weeks of treatment and were &gt;= 80% compliant with the study medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Triglycerides Between Baseline and 52 Week Assessments</title>
          <description>Percent Change in Triglycerides Between Baseline and 52 week assessments: 100% x [(Triglycerides 52 Weeks – Triglycerides Baseline) / (Triglycerides Baseline)].</description>
          <population>Per Protocol</population>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1511"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="43.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Single Cohort Study. Statistical Analysis is based on change from baseline. Null Hypothesis value is 0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.336</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.1</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>43.5</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change in Total Cholesterol Between Baseline and 52 Week Assessments</title>
        <description>Percent Change in Total Cholesterol Between Baseline and 52 week assessments: 100% x [(Total Cholesterol 52 weeks – Total Cholesterol Baseline) / (Total Cholesterol Baseline)].</description>
        <time_frame>52 Weeks - Baseline</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan +/- Hydrochlorothiazide</title>
            <description>Patients that completed 52 weeks of treatment and were &gt;= 80% compliant with the study medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Total Cholesterol Between Baseline and 52 Week Assessments</title>
          <description>Percent Change in Total Cholesterol Between Baseline and 52 week assessments: 100% x [(Total Cholesterol 52 weeks – Total Cholesterol Baseline) / (Total Cholesterol Baseline)].</description>
          <population>Per Protocol</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1511"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.98" spread="16.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Single Cohort Study. Statistical Analysis is based on change from baseline. Null Hypothesis value is 0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.0</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>17.0</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Absolute Change in Uric Acid Between Baseline and 52 Week Assessments</title>
        <description>Absolute Change in Uric Acid Between Baseline and 52 week assessments: Uric Acid 52 weeks – Uric Acid Baseline.</description>
        <time_frame>52 Weeks - Baseline</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan +/- Hydrochlorothiazide</title>
            <description>Patients that completed 52 weeks of treatment and were &gt;= 80% compliant with the study medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Uric Acid Between Baseline and 52 Week Assessments</title>
          <description>Absolute Change in Uric Acid Between Baseline and 52 week assessments: Uric Acid 52 weeks – Uric Acid Baseline.</description>
          <population>Per Protocol</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1511"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.17" spread="63.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Single Cohort Study. Statistical Analysis is based on change from baseline. Null Hypothesis value is 0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-19.2</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>63.8</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Absolute Change in C Reactive Protein Between Baseline and 52 Week Assessments</title>
        <description>Absolute Change in C Reactive Protein Between Baseline and 52 week assessments: C Reactive Protein 52 weeks – C Reactive Protein Baseline.</description>
        <time_frame>52 Weeks - Baseline</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan +/- Hydrochlorothiazide</title>
            <description>Patients that completed 52 weeks of treatment and were &gt;= 80% compliant with the study medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in C Reactive Protein Between Baseline and 52 Week Assessments</title>
          <description>Absolute Change in C Reactive Protein Between Baseline and 52 week assessments: C Reactive Protein 52 weeks – C Reactive Protein Baseline.</description>
          <population>Per Protocol</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1511"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Single Cohort Study. Statistical Analysis is based on change from baseline. Null Hypothesis value is 0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.613</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>8.7</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Overall ITT</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="1714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1714"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.">Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1714"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1714"/>
              </event>
              <event>
                <sub_title>Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1714"/>
              </event>
              <event>
                <sub_title>Single Vessel Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1714"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1714"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1714"/>
              </event>
              <event>
                <sub_title>Ulcer Bleeding Gastric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1714"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1714"/>
              </event>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1714"/>
              </event>
              <event>
                <sub_title>Lymphoma grade IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral vascular accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1714"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1714"/>
              </event>
              <event>
                <sub_title>Numbness of Upper Arm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1714"/>
              </event>
              <event>
                <sub_title>Subarachnoid Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis asthmatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac catheterization</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1714"/>
              </event>
              <event>
                <sub_title>Hip Replacement</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1714"/>
              </event>
              <event>
                <sub_title>Ileostomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1714"/>
              </event>
              <event>
                <sub_title>Rotator Cuff Repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Atherosclerotic cardiovascular disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1714"/>
              </event>
              <event>
                <sub_title>Superficial Femoral Arterial Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1714"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="198" subjects_at_risk="1714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Glucose Increased (per investigator's clinical judgment)</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="1714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="1714"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="1714"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

